Future Treatment Options for Patients With RCC
Hans Hammers, MD, PhD, associate professor at the University of Texas Southwestern Medical Center, discusses what he believes is most important in future investigation for the treatment of patients with renal cell carcinoma. With combination therapies on the rise in the field of kidney cancers, new pivotal and early clinical trials are constantly arising looking at new combination regimens.
Hans Hammers, MD, PhD, associate professor at the University of Texas Southwestern Medical Center, discusses what he believes is most important in future investigation for the treatment of patients with renal cell carcinoma (RCC). With combination therapies on the rise in the field of kidney cancers, new pivotal and early clinical trials are constantly arising looking at new combination regimens.
A number of agents are heading toward clinical development that are also being tested in clinical trials as a part of potential combinations, especially with various immune checkpoint inhibitors. For example, Hammers pointed to an ongoing phase III trial of an IDO inhibitor, epacadostat, in combination with pembrolizumab (Keytruda), a PD-1 inhibitor, as a frontline treatment in comparison with sunitinib (Sutent), a current first-line standard-of-care targeted therapy in RCC. Hammers also suggested exploring the potential of vaccination with combinations of checkpoint inhibitors.
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
